- Home
- INCR vs CVM Comparison
INCR vs CVM Comparison
Compare INCR & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- CVM
- Stock Information
- Founded
- INCR 1994
- CVM 1983
- Country
- INCR Israel
- CVM United States
- Employees
- INCR N/A
- CVM N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INCR Health Care
- CVM Health Care
- Exchange
- INCR Nasdaq
- CVM Nasdaq
- Market Cap
- INCR 80.1M
- CVM 68.9M
- IPO Year
- INCR N/A
- CVM 1987
- Fundamental
- Price
- INCR $1.26
- CVM $0.56
- Analyst Decision
- INCR
- CVM
- Analyst Count
- INCR 0
- CVM 0
- Target Price
- INCR N/A
- CVM N/A
- AVG Volume (30 Days)
- INCR 36.9K
- CVM 450.5K
- Earning Date
- INCR 11-26-2024
- CVM 12-19-2024
- Dividend Yield
- INCR N/A
- CVM N/A
- EPS Growth
- INCR N/A
- CVM N/A
- EPS
- INCR N/A
- CVM N/A
- Revenue
- INCR $72,420,918.00
- CVM N/A
- Revenue This Year
- INCR N/A
- CVM N/A
- Revenue Next Year
- INCR $39.30
- CVM $3,412.81
- P/E Ratio
- INCR N/A
- CVM N/A
- Revenue Growth
- INCR N/A
- CVM N/A
- 52 Week Low
- INCR $1.06
- CVM $0.54
- 52 Week High
- INCR $3.72
- CVM $3.23
- Technical
- Relative Strength Index (RSI)
- INCR 20.78
- CVM 16.48
- Support Level
- INCR $1.70
- CVM $0.68
- Resistance Level
- INCR $1.78
- CVM $0.92
- Average True Range (ATR)
- INCR 0.08
- CVM 0.06
- MACD
- INCR -0.04
- CVM -0.02
- Stochastic Oscillator
- INCR 5.77
- CVM 0.06
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.